Can metabolic syndrome predict the vulnerable plaque in patients with stable angina pectoris? Virtual histology-intravascular ultrasound analysis  by Lee, Min Goo et al.
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Summary
Background:  Vulnerable  plaque  in  coronary  artery  can  progress  to  plaque  rupture  and  throm-
bosis, and  have  a  strong  potential  to  induce  acute  coronary  syndrome.  Many  studies  have
demonstrated  that  metabolic  syndrome  (MetS)  is  associated  with  increased  risk  for  cardio-
vascular diseases  and  related  mortalities.
Methods:  From  September  2007  to  June  2010,  a  total  of  239  patients  with  stable  angina  pectoris
(SAP) who  underwent  coronary  angiogram  and  intravascular  ultrasound  (IVUS)  were  categorized
into two  groups:  MetS  group  (n  =  100,  56  men,  64.7  ±  9.5  years)  and  non-MetS  group  (n  =  139,  98
men, 60.2  ±  8.4  years).
Results:  MetS  group  showed  more  frequent  multivessel  involvement  (p  =  0.026)  and  had  more
distal target  vessel  in  coronary  artery  (p  =  0.005)  than  non-MetS  group,  but  IVUS  ﬁndings  showed
no signiﬁcant  difference  between  the  two  groups.  In  addition,  low  high-density  lipoprotein
(HDL) cholesterol  level  as  the  criteria  of  MetS  was  observed  in  virtual  histology  (VH)-derived
thin cap  ﬁbroatheroma  (TCFA)  group  more  than  stable  plaque  group  (p  =  0.020),  but  the  preva-
lence of  MetS  and  other  components  of  MetS  were  not  different  between  the  two  groups.
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Multivariate  analysis  using  logistic  regression  for  the  presence  of  VH-derived  TCFA  showed  that
the independent  predictor  is  the  low  HDL  cholesterol  level  (odds  ratio  =  3.563,  95%  conﬁdence
interval =  1.370—9.269,  p  =  0.009).
Conclusions:  The  presence  of  MetS  was  not  associated  with  VH-derived  TCFA  in  patients  with
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and  0.97,  respectively.  Similarly,  for  plaque  components
by  VH-IVUS,  reproducibility  for  the  ﬁbrous  (FT),  ﬁbro-fatty
(FF),  dense  calcium  (DC),  and  necrotic  core  (NC)  volumeSAP.
© 2011  Japanese  College  of  C
Introduction
Most  of  the  acute  coronary  syndromes  (ACS)  are  thought  to
be  the  result  of  sudden  luminal  thrombosis  [1—5], and  lumi-
nal  thrombosis  occurs  from  plaque  rupture,  erosion,  and
calciﬁed  nodules.  Vulnerable  plaque  (VP)  has  been  identi-
ﬁed  as  a  possible  cause  of  sudden  cardiac  death,  because
VP  is  susceptible  to  sudden  rupture,  swiftly  forming  a clot
that  blocks  the  ﬂow  of  blood  through  a  coronary  artery.  VP
is  different  from  the  ﬁbrotic,  calciﬁed  plaque  that  grows
gradually  until  a  lesion  completely  occludes  an  artery.  It  has
been  observed  that  some  plaques  at  other  sites  in  the  coro-
nary  tree  resemble  the  rupture  plaque  but  lack  a  luminal
thrombus:  these  lesions  have  been  designated  as  thin  cap
ﬁbroatheroma  (TCFA)  or  VP  [5].  The  TCFA  has  been  pos-
tulated  to  be  the  precursor  lesion  of  plaque  rupture  and
is  most  frequently  observed  in  patients  with  acute  plaque
rupture  [6].  Many  studies  have  shown  metabolic  syndrome
(MetS)  to  be  a  risk  factor  for  coronary  artery  disease  [7—10],
but  no  data  are  available  on  the  direct  effect  of  MetS  on
the  vulnerability  of  the  plaque  in  the  patients  with  stable
angina  pectoris  (SAP).  Virtual  histology-intravascular  ultra-
sound  (VH-IVUS)  can  provide  quantitative  information  on
plaque  composition;  it  has  been  validated  in  studies  of
explanted  human  coronary  segments  [11].
The  aim  of  the  present  study  was  to  assess  the  relation-
ship  between  the  presence  of  MetS  and  VP  in  patients  with
SAP  by  using  VH-IVUS.
Methods
Study  population
This  study  was  a  retrospective,  single-center  study.  From
September  2007  to  June  2010,  we  identiﬁed  239  consecu-
tive  patients  with  SAP  who  underwent  coronary  angiogram
and  VH-IVUS.  The  presence  of  SAP  was  determined  when  typ-
ical  effort-induced  chest  pain  which  was  relieved  by  resting
was  present,  and  functional  studies  such  as  treadmill  test
or  myocardial  single-photon  emission  computed  tomography
revealed  ﬁndings  compatible  with  ischemia.  IVUS  exam  was
performed  in  patients  with  intermediate  coronary  stenosis,
which  was  deﬁned  as  diameter  stenosis  30—70%  on  quan-
titative  coronary  angiography  (QCA),  at  Chonnam  National
University  Hospital,  Gwangju,  Korea.  Lesions  examined  by
IVUS  were  the  culprit  lesions.  Patients  were  divided  into
MetS  group  (n  =  100)  and  non-MetS  group  (n  =  139)  accord-
ing  to  the  presence  of  MetS.  We  excluded  patients  with
restenosis  after  stenting,  coronary  artery  bypass  graft  fail-
ure,  factors  associated  with  increased  risk  of  bleeding,
severe  heart  failure  or  cardiogenic  shock,  important  sys-
temic  disease,  or  serum  creatinine  ≥2.0  mg/dl,  and  patients
in  whom  adequate  IVUS  images  could  not  be  obtained.  The
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rotocol  was  approved  by  the  institutional  review  board.
ospital  records  of  patients  were  reviewed  to  obtain  clinical
emographics  and  medical  history.
aboratory  analysis
eripheral  blood  samples  were  obtained  before  IVUS  study
sing  direct  venipuncture.  The  blood  samples  were  cen-
rifuged,  and  serum  was  removed  and  stored  at  −70◦C
ntil  the  assay  could  be  performed.  The  serum  levels
f  total  cholesterol,  triglyceride,  low-density  lipoprotein
LDL)  cholesterol,  and  high-density  lipoprotein  (HDL)  choles-
erol  were  measured  by  standard  enzymatic  methods.
igh-sensitivity  C-reactive  protein  (CRP)  was  analyzed  tur-
idimetrically  with  sheep  antibodies  against  human  CRP;
his  has  been  validated  against  the  Dade-Behring  method
12].  Serum  N-terminal  pro-B-type  natriuretic  peptide  was
easured  using  an  electrochemiluminescence  sandwich
mmunoassay  method  with  an  Elecsys  2010  analyzer  (Roche
iagnostics,  Mannheim,  Germany).
uantitative  coronary  angiographic  analysis
oronary  angiogram  was  analyzed  with  validated  QCA  sys-
em  (Philips  H5000  or  Allura  DCI  program,  Philips  Medical
ystem,  Eindhoven,  the  Netherlands).  With  the  outer  diam-
ter  of  the  contrast-ﬁlled  catheter  as  the  calibration
tandard,  the  minimal  lumen  diameter,  reference  diameter,
nd  lesion  length  were  measured  in  diastolic  frames  from
rthogonal  projections.  Perfusion  was  evaluated  according
o  thrombolysis  in  myocardial  infarction  (TIMI)  criteria.
VUS  Imaging  and  analysis
ll  gray-scale  and  VH-IVUS  examinations  were  performed
fter  intracoronary  administration  of  300  g nitroglycer-
ne.  A  20-MHz,  2.9F  IVUS  imaging  catheter  (Eagle  Eye,
olcano  Corp,  Rancho  Cordova,  CA,  USA)  was  advanced
10  mm  beyond  the  lesion;  and  automated  pullback  was  per-
ormed  to  a  point  >10  mm  proximal  to  the  lesion  at  a  speed
f  0.5  mm/s.  IVUS  data  were  analyzed  by  2  independent
bservers  (H.Y.J  and  C.Y.H).  The  levels  of  reproducibility  for
xternal  elastic  membrane  (EEM),  lumen,  and  plaque  plus
edia  (P&M)  cross-sectional  areas  (CSAs)  using  the  Spear-
an  rank-order  correlation  coefﬁcients  were  0.96,  0.97,easurements  using  the  Spearman  rank-order  correlation
oefﬁcients  were  0.93,  0.94,  0.93,  and  0.93,  respectively.
uantitative  volumetric  gray-scale  and  VH-IVUS  analysis
ere  performed  across  the  entire  lesion  segment,  and
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ross-sectional  analysis  was  performed  at  the  minimum
umen  sites  and  at  the  largest  NC  sites.
Conventional  quantitative  volumetric  gray-scale  IVUS
nalysis  was  performed  according  to  the  American  College  of
ardiology  Clinical  Expert  Consensus  Document  on  Standards
or  Acquisition,  Measurement  and  Reporting  of  Intravascular
ltrasound  Studies  [13]. Measurements  were  made  by  every
-mm  interval  for  the  region  of  interest,  which  was  deﬁned
s  the  segment  between  distal  to  proximal  reference  sites
hat  were  the  most  normal  looking  10  mm  proximal  and  dis-
al  to  the  lesion.  Volumetric  data  were  generated  by  the
oftware  using  Simpson’s  method.  EEM  and  lumen  CSA  were
easured.  P&M  CSA  was  calculated  as  EEM  minus  lumen  CSA;
nd  plaque  burden  was  calculated  as  P&M  divided  by  EEM
SA.  Hypoechoic  plaque  was  less  bright  than  the  adventitia,
yperechoic  noncalciﬁed  plaque  was  as  bright  as  or  brighter
han  the  adventitia  without  acoustic  shadowing,  and  hypere-
hoic  calciﬁed  plaque  was  brighter  than  the  adventitia  with
coustic  shadowing.  When  there  was  no  dominant  plaque
omponent,  we  classiﬁed  it  as  mixed  plaque.
VH-IVUS  analysis  classiﬁed  the  color-coded  tissue  into
our  major  components:  green  (FT);  yellow-green  (FF);
hite  (DC);  and  red  (NC)  [11,14].  VH-IVUS  analysis  was
eported  in  absolute  amounts  and  as  a  percentage  of  plaque
rea  or  volume.  TCFA  was  deﬁned  as  focal,  NC-rich  (≥10%  of
he  CSA)  plaque  area  in  at  least  3  consecutive  frames  with-
ut  overlying  ﬁbrous  tissue  in  the  presence  of  plaque  burden
40%  [14].
eﬁnition  of  MetS
or  the  diagnosis  of  MetS  at  baseline,  we  used  the  US
ational  Cholesterol  Education  Program-Adult  Treatment
anel  (NCEP-ATP)  III  criteria.  Central  obesity  was  deﬁned  as
aist  circumference  >90  cm  in  men  or  >80  cm  in  women  by
odiﬁed  ATP  III  guideline  that  WHO-Western  Paciﬁc  Region
WPR)  and  International  Association  for  the  Study  of  Obe-
ity  (IASO)  presented  for  Asian  populations  in  2000.  The
resence  of  MetS  was  analyzed  considering  the  presence
f  the  following  criteria:  (1)  central  obesity:  waist  cir-
umference  >90  cm  (men),  >80  cm  (women);  (2)  a  fasting
riglyceride  level  ≥150  mg/dl;  (3)  reduced  HDL  cholesterol:
40  mg/dl  (men),  <50  mg/dl  (women);  (4)  hypertension:
lood  pressure  ≥130/85  mmHg  or  taking  antihypertensive
edication;  and  (5)  impaired  fasting  glucose  (IFG):  fast-
ng  glucose  ≥100  mg/dl  or  taking  medication  or  past  history
f  type  2  diabetes  mellitus  (DM).  Patients  were  consid-
red  to  have  MetS  in  the  presence  of  ≥3  of  criteria,
ccording  to  the  deﬁnition  proposed  by  the  American
eart  Association/National  Heart,  Lung,  and  Blood  Institute
AHA/NHLBI).
tatistical  analysis
he  Statistical  Package  for  Social  Sciences  (SPSS)  for  Win-
ows,  version  17.0  (SPSS  Inc.,  Chicago,  IL,  USA)  was  used
or  all  analysis.  Continuous  variables  were  presented  as
he  mean  value  ±  1  SD;  comparisons  were  conducted  by
tudent’s  t-test  or  the  Wilcoxon  rank-sum  test  if  nor-
ality  assumption  was  violated.  Discrete  variables  were
resented  as  percentages  and  frequencies;  comparisons
T
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ere  conducted  by  2 statistics  or  Fisher’s  exact  test  as
ppropriate.  A  multivariable  logistic  regression  analysis  was
erformed  to  identify  the  independent  predictors  of  cul-
rit  lesion  TCFA.  A  p-value  <0.05  was  considered  statistically
igniﬁcant.
esults
linical  characteristics
he  baseline  characteristics  are  summarized  in  Table  1.
atients  with  MetS  were  signiﬁcantly  older  and  there
ere  more  females  compared  with  those  without  MetS.
polipoprotein  (Apo)  A1  was  lower,  but  homocysteine,  Apo
/A1  ratio,  and  glycosylated  hemoglobin  level  were  higher
n  the  MetS  group  than  the  non-MetS  group.  Dyslipidemia  was
eﬁned  as  history  of  dyslipidemia,  not  by  laboratory  ﬁndings
uring  admission.  Therefore,  the  prevalence  of  dyslipidemia
as  low.  Between  the  two  groups,  no  signiﬁcant  differences
ere  present  in  the  type  of  medications  that  can  affect  the
laque  morphology.
oronary  angiographic  ﬁndings
ngiographic  ﬁndings  are  summarized  in  Table  2.  Multivessel
isease  was  more  common  in  patients  with  MetS  compared
ith  those  without  MetS.  MetS  group  had  more  distal  tar-
et  vessel  in  coronary  artery  than  non-MetS  group,  but  less
roximal  target  vessel  than  non-MetS  group.  There  were
o  meaningful  trends  in  target  vessel  and  TIMI  ﬂow  grade
ccording  to  the  presence  of  MetS.
ray-scale  IVUS  results
ray-scale  IVUS  results  are  summarized  in  Table  3.  There
ere  no  signiﬁcant  differences  in  gray-scale  IVUS  ﬁndings
etween  the  two  groups,  but  EEM  volume,  lumen  volume,
nd  plaque  volume  tended  to  be  greater  in  patients  with
etS  compared  with  those  without  MetS.
H-IVUS  results
t  the  minimum  lumen  site,  absolute  FT  area  was  signif-
cantly  greater  in  patients  with  MetS  compared  with  those
ithout  MetS  (Fig.  1).  At  the  largest  necrotic  core  site,  abso-
ute  NC  area  was  signiﬁcantly  greater  in  patients  with  MetS
ompared  with  those  without  MetS,  but  %NC  volume  was  not
igniﬁcantly  greater  in  patients  with  MetS  compared  to  those
ithout  MetS  (Fig.  2).  Absolute  FT  volume  was  signiﬁcantly
reater  in  patients  with  MetS  compared  with  those  without
etS  (Fig.  3).
omponents  of  MetS  and  independent  predictors  of
H-derived TCFAhe  relation  between  components  of  MetS  and  VH-derived
CFA  are  listed  in  Table  4.  VH-derived  TCFA  is  not  a  frequent
laque  type  lesion  submitted  to  intervention  (11.7%).  Only
DL  cholesterol  level  as  the  criteria  of  MetS  was  observed
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Table  1  Baseline  characteristics.
MetS  group  (n  =  100)  Non-MetS  group  (n  =  139)  p-Value
Age  (years)  64.7  ±  9.5  60.2  ±  8.4  <  0.001
Male gender,  n  (%)  56  (56)  98  (71)  0.021
Diabetes mellitus,  n  (%)  57  (57)  20  (14)  <  0.001
Hypertension,  n  (%)  84  (84)  52  (37)  <0.001
Dyslipidemia,  n  (%)  21  (21)  26  (19)  0.781
Body weight  (kg)  67.5  ±  10.1  66.4  ±  10.5  0.406
BMI (kg/m2)  25.9  ±  2.7  24.7  ±  2.9  0.003
Waist circumference  (cm) 94.2  ±  8.0 88.4  ±  8.6  <0.001
Smoking, n  (%) 18  (18) 37  (27) 0.118
Familial history  of  coronary  artery  disease,  n  (%) 4  (4) 3  (2) 0.2
Ejection fraction  (%) 59  ±  10 61  ±  11 0.09
Creatinine  (mg/dl)  0.87  ±  0.29  0.82  ±  0.20  0.133
Total cholesterol  (mg/dl)  176.5  ±  38.8  185.5  ±  36.9  0.069
Triglyceride  (mg/dl)  145.3  ±  29.9  138.1  ±  30.2  0.002
LDL cholesterol  (mg/dl)  112.0  ±  33.9  119.5  ±  31.8  0.08
HDL cholesterol  (mg/dl)  40.5  ±  8.8  50.1  ±  12.0  <0.001
Apolipoprotein  A1  (mg/dl)  120.1  ±  19.7  128.3  ±  20.3  0.002
Apolipoprotein  B  (mg/dl)  92.0  ±  24.2  90.7  ±  20.1  0.66
Apolipoprotien  B/A1  0.79  ±  0.26  0.73  ±  0.20  0.044
Lipoprotein (a)  (mg/dl)  24.6  ±  29.1  28.4  ±  24.7  0.285
Homocysteine  (mol/l)  10.7  ±  6.1  8.9  ±  2.7  0.002
NT-pro-BNP  (pg/ml)  424.2  ±  651.4  327.0  ±  689.1  0.241
HbA1c (g/dl) 6.8  ±  1.5  5.9  ±  0.9  <0.001
hs-CRP (mg/dl) 0.32  ±  0.88 0.22  ±  0.85  0.425
Medications,  n  (%)
Aspirin  96  (96)  132  (95)  0.784
Clopidogrel 52  (52)  67  (48)  0.475
ACEI or  ARB 49  (49) 77  (55)  0.298
Beta blocker 45  (45) 57  (41) 0.354
Statin 38  (38) 49  (35)  0.402
Fibrate 7  (7) 7  (5) 0.199
Data are given as mean ± SD or n (%). MetS, metabolic syndrome; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; HbA1c, glycosylated hemoglobin; hs-CRP, high-sensitivity C-reactive
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in  VH-derived  TCFA  group  more  than  stable  plaque  group,
but  the  prevalence  of  MetS  and  other  components  of  MetS
were  not  different  between  the  two  groups.  The  following
variables  were  tested  to  determine  the  independent  pre-
dictors  of  VH-derived  TCFA  (variables  with  p  value  <0.1  in
univariate  analysis):  low  HDL  cholesterol  level,  proximal
lesion  location,  left  main  stem  disease,  smoking,  abundant
plaque  burden,  old  age  (>65),  and  male  gender  (Table  5).
Multivariate  analysis  using  logistic  regression  showed  that
the  independent  predictor  of  VH-derived  TCFA  is  the  low
HDL  cholesterol  level  (odds  ratio  =  3.563,  95%  conﬁdence
interval  =  1.370—9.269,  p  =  0.009).
Discussion
The  major  ﬁndings  of  this  study  are  as  follows:  (1)  VH-
derived  TCFA  is  not  a  frequent  plaque  type  lesion  submitted
to  intervention  in  SAP  patients;  (2)  MetS  is  not  meaningfully
associated  with  VH-derived  TCFA  in  SAP  patients;  and  (3)
low  HDL  cholesterol  level  is  the  independent  predictor  of
VH-derived  TCFA  as  culprit  lesion  in  SAP  patients.
i
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isin receptor blocker.
The  high-risk  atheromatous  plaque,  often  referred  to  as
P,  is  described  as  TCFA,  the  main  component  of  which
onsists  of  lipid-rich  atheromatous  core,  thin  ﬁbrous  cap
ith  macrophage  and  lymphocyte  inﬁltration,  decreased
mooth  muscle  cell  content,  and  extensive  remodeling  of
he  arterial  wall  [15]. This  combination  of  a  large  lipid
ore  and  thin  ﬁbrous  cap  predisposes  to  physical  disrup-
ion  of  atherosclerotic  plaque  (i.e.  endothelial  erosions
nd  ﬁbrous  cap  rupture),  resulting  in  an  ACS.  Intravascu-
ar  plaque  rupture  exposes  the  thrombogenic  lipid  core  and
ub-endothelium  to  the  blood,  resulting  in  thrombosis,  vas-
ular  obstruction,  and  possibly  critical  ischemia.  It  has  been
ell-known  that  atherosclerotic  plaques  responsible  for  the
ajority  of  life-threatening  syndromes  are  characterized  by
nﬂammation  [15—18]. Especially,  this  concept  has  moved
he  focus  to  new  imaging  techniques,  such  as  IVUS,  that
an  identify  those  lesions  with  an  increased  risk  of  caus-
ng  an  acute  event  in  the  near  future.  Although  VH-IVUS
annot  directly  measure  the  inﬂammatory  status  of  plaque,
t  can  provide  detailed  qualitative  and  quantitative  plaque
nformation  and  identify  four  speciﬁc  plaque  components.
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Table  2  Coronary  angiographic  ﬁndings.
MetS  group  (n  =  100)  Non-MetS  group  (n  =  139)  p-Value
Target  coronary  artery,  n  (%)
Left  main  stem  5  (5)  9  (7)  0.985
Left anterior  descending  75  (75)  112  (81)  0.123
Left circumﬂex  10  (10)  9  (7)  0.309
Right 10  (10)  9  (7)  0.309
Lesion location,  n  (%)
Ostium 6  (6)  13  (10)  0.218
Proximal 30  (30) 55  (40)  0.018
Middle 49 (49) 64  (46) 0.981
Distal 15  (15) 7  (5) 0.005
Multivessel  disease,  n  (%) 43  (43) 40  (29) 0.026
0.081
0 5  (5)  6  (4)
I 7  (7)  8  (6)
II 9  (9)  7  (5)
III 79  (79)  118  (85)
Lesion length  (mm)  25.1  ±  13.0  24.8  ±  15.1  0.858
Reference diameter  (mm)  3.13  ±  0.46  3.16  ±  0.47  0.538
Pre-MLD (mm)  0.93  ±  0.45  0.97  ±  0.46  0.514
Diameter stenosis  (%)  71.2  ±  11.9  69.7  ±  14.0  0.085
Data are given as mean ± SD or n (%). MetS, metabolic syndrome; TIMI, thrombolysis in myocardial infarction; MLD, minimal lumen
diameter.
Figure  1  Virtual  histology  plaque  component  analysis  accord-
ing to  the  presence  of  MetS  at  the  minimum  lumen  sites.  Results
are displayed  for  (A)  absolute  and  (B)  relative  quantiﬁcations.
MetS,  metabolic  syndrome;  FT,  ﬁbrotic;  FF,  ﬁbro-fatty;  DC,
dense  calcium;  NC,  necrotic  core.
Figure  2  Virtual  histology  plaque  component  analysis  accord-
ing to  the  presence  of  MetS  at  the  largest  necrotic  core  sites.
Results  are  displayed  for  (A)  absolute  and  (B)  relative  quantiﬁ-
cations.  MetS,  metabolic  syndrome;  FT,  ﬁbrotic;  FF,  ﬁbro-fatty;
DC, dense  calcium;  NC,  necrotic  core.
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Table  3  Gray-scale  intravascular  ultrasound  ﬁndings.
MetS  group  (n  =  100)  Non-MetS  group  (n  =  139)  p-Value
Proximal  reference
EEM  CSA  (mm2)  19.3  ±  6.2  17.8  ±  4.6  0.183
Lumen CSA  (mm2)  11.2  ±  3.7  10.6  ±  3.0  0.366
P&M CSA  (mm2)  8.1  ±  3.2  7.2  ±  2.4  0.137
Plaque burden  (%) 41.3  ±  6.7  40.3  ±  7.5  0.525
Minimum lumen  site
EEM  CSA  (mm2)  15.1  ±  4.9 14.0  ±  5.6 0.341
Lumen CSA  (mm2)  4.3  ±  1.5 4.6  ±  3.2 0.541
P&M CSA  (mm2)  10.8  ±  4.3  9.4  ±  4.3  0.324
Plaque burden  (%)  67.9  ±  15.0  67.0  ±  10.6  0.613
Distal reference
EEM  CSA  (mm2)  13.3  ±  4.3  12.9  ±  6.2  0.713
Lumen CSA  (mm2)  8.4  ±  2.8  8.0  ±  3.8  0.656
P&M CSA  (mm2)  5.0  ±  1.9  4.8  ±  2.8  0.798
Plaque burden  (%)  37.1  ±  6.7  36.5  ±  7.2  0.727
Largest necrotic  core  site
EEM  CSA  (mm2)  17.1  ±  5.6  15.6  ±  4.6  0.216
Lumen CSA  (mm2)  5.6  ±  2.4  5.5  ±  2.6  0.782
P&M CSA  (mm2)  11.4  ±  4.4  10.1  ±  3.6  0.136
Plaque burden  (%)  66.4  ±  9.7  64.5  ±  10.5  0.390
Plaque morphology,  n  (%)
Hypoechoic  41  (41)  61  (44)  0.656
Hyperechoic,  non-calciﬁed 6  (6)  8  (6)  0.937
Hyperechoic,  calciﬁed 7  (7) 10  (7)  0.954
Mixed 46  (46)  60  (43)  0.663
Volumetric analysis
EEM  volume  (mm3)  404.7  ±  240.4  306.1  ±  168.3  0.021
Lumen volume  (mm3)  180.1  ±  112.1 135.3  ±  67.5  0.042
Plaque volume  (mm3)  224.6  ±  131.2 170.8  ±  103.2 0.032
e; EE
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fData are given as mean ± SD or n (%). MetS, metabolic syndrom
plaque plus media.
MetS  is  rapidly  increasing  in  frequency.  Also,  patients
with  MetS  have  been  shown  to  have  higher  cardiovascular
risk  when  associated  with  signiﬁcant  angiographic  coronary
artery  disease  [19—22]. Considering  that  MetS  is  frequent  in
real-world  practice,  it  can  be  an  important  issue  to  inves-
tigate  whether  MetS  is  related  with  VP.  However,  there  are
very  limited  data  regarding  this  interrogation.  Therefore,
we  assessed  the  relationship  between  the  presence  of  MetS
and  VP  in  the  patients  with  SAP  by  using  VH-IVUS.
Several  studies  have  demonstrated  the  coronary  plaque
components  assessed  by  VH-IVUS  in  patients  with  ACS
l
s
t
Table  4  Components  of  MetS  according  to  the  presence  of  VH-de
TCFA  group  (n  =  28)  
MetS  12  (43)  
Waist circumference  18  (64)  
Hypertension  16  (57)  
Diabetes mellitus 12  (43)  
Hypertriglyceridemia 13  (46)
Low HDL  cholesterol  19  (68)  
Data are given as n (%). MetS, metabolic syndrome; VH, virtual histologM, external elastic membrane; CSA, cross-sectional area; P&M,
23,24]. Rodriguez-Granillo  et  al.  reported  that  VH-IVUS
dentiﬁed  TCFA  as  a  more  prevalent  ﬁnding  in  patients  with
CS  compared  with  stable  angina  [14]. TCFA  is  the  precursor
f  plaque  rupture,  which  accounts  for  a  majority  of  coronary
hrombi  and  coronary  death  [5,6]. In  the  Providing  Regional
bservations  to  Study  Predictors  of  Events  in  the  Coro-
ary  Tree  (PROSPECT)  trial,  VH-derived  TCFA  are  related  to
uture  cardiovascular  events,  overcoming  the  well-known
imitation  of  VH  to  detect  thin  ﬁbrous  cap  due  to  lack  of
patial  resolution  [25]. Also,  Yamada  et  al.  reported  that
arget  lesion  TCFA  may  be  related  to  the  long-term  clinical
rived  TCFA.
Stable  plaque  group  (n  =  211)  p-Value
88  (42)  0.908
129  (61)  0.748
120  (57)  0.978
65  (31)  0.209
92  (44)  0.459
94  (45)  0.020
y; TCFA, thin cap ﬁbroatheroma; HDL, high-density lipoprotein.
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Table  5  Independent  predictors  of  VH-derived  TCFA  by  multivariate  analysis  (logistic  regression).
Odds  ratio  95%  conﬁdence  interval  p-Value
Low  HDL  cholesterol 3.563  1.370—9.269  0.009
Proximal lesion  location  2.051  0.776—5.422  0.148
Male gender 2.068  0.715—5.976  0.180
Plaque burdena 0.213
60—80% 2.739  0.328—22.904 0.352
>80% 5.468  0.579—51.629 0.138
Smoking 1.759  0.715—4.327 0.219
Left main  stem  1.511  0.672—3.400  0.318
Old age  (>65  years)  1.134  0.511—2.518  0.757
VH, virtual histology; TCFA, thin cap ﬁbroatheroma; HDL, high-density lipoprotein.
a Plaque burden was estimated at largest necrotic core site by intrav
outcomes  after  successful  percutaneous  coronary  interven-
tion  in  patients  with  angina  pectoris  [26]. Therefore,  the
detection  of  TCFA  by  VH-IVUS  may  be  important  in  regard  to
improve  the  prognosis  of  ischemic  heart  diseases.
HDL  provides  the  principal  means  by  which  excess  choles-
terol  can  be  removed  from  peripheral  tissues,  including
the  foam  cells  of  the  evolving  atherosclerotic  plaque,  and
returned  to  the  liver  for  catabolism  or  recycling  [27]. At
Figure  3  Volumetric  virtual  histology  plaque  component  anal-
ysis according  to  the  presence  of  MetS.  Results  are  displayed  for
(A) absolute  and  (B)  relative  quantiﬁcations.  MetS,  metabolic
syndrome;  FT,  ﬁbrotic;  FF,  ﬁbro-fatty;  DC,  dense  calcium;  NC,
necrotic  core.
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fascular ultrasound.
he  molecular  level,  HDL  inhibits  atherosclerosis  at  multi-
le  sites,  including  reduced  adhesion  of  inﬂammatory  cells
o  the  endothelium  and  their  migration  into  the  arterial
ntima,  reduced  inﬂammation  within  the  artery  wall,  and
nhibition  of  LDL  oxidation  [27]. The  promotion  of  reverse
holesterol  transport  by  HDL  implies  a  beneﬁcial  effect  on
theroma  volume,  whereas  the  anti-inﬂammatory  effects
f  HDL  may  promote  plaque  stability  and  reduced  risk  of
laque  rupture.  Although  MetS  did  not  predict  the  presence
f  VH-derived  TCFA  in  patients  with  SAP,  our  study  sug-
ested  that  low  concentrations  of  HDL  cholesterol,  but  not
igh  concentrations  of  LDL  cholesterol,  might  be  associated
ith  vulnerable  coronary  plaque  in  patients  with  SAP.  Thus,
atients  with  low  concentrations  of  HDL  cholesterol  might
ave  a  high  risk  of  plaque  rupture  and  thrombus  formation,
hich  can  lead  to  ACS  and  even  cardiac  death,  because  of
he  disruption  of  TCFA.  In  contrast  with  our  study,  previous
pidemiological  studies  have  shown  that  long-term  morbid-
ty  and  mortality  in  coronary  artery  disease,  manifest  over
ears,  is  directly  related  to  circulating  levels  of  atherogenic
ipoproteins,  in  particular  LDL  cholesterol  [28]. Also,  Kato
t  al.  showed  that  high  LDL  cholesterol  level  is  an  indepen-
ent  predictor  of  vulnerability  to  coronary  plaque  formation
n  ACS  patients  without  MetS  [29]. However,  the  Tromsø
tudy  provided  evidence  for  antiatherogenic  effects  of  HDL,
elating  to  both  inhibition  of  plaque  growth  and  enhanced
laque  stability  [30]. These  ﬁndings  are  further  extended
y  a  recent  population-based  observational  cohort  study  in
he  UK  in  18,815  patients  [31]. Also,  Olsson  et  al.  showed
hat  plasma  HDL  cholesterol,  but  not  LDL  cholesterol,  mea-
ured  in  the  initial  stage  of  ACS  predicts  the  risk  of  recurrent
ardiovascular  events  [32]. Our  results  suggest  their  ﬁnd-
ng  can  be  applicable  to  the  patients  with  SAP  as  well  as
CS.
Low  HDL  cholesterol  is  an  independent  risk  factor  for
therothrombotic  coronary  events,  and  correction  of  low
DL  cholesterol  reduced  coronary  event  rates  signiﬁcantly
n  a  number  of  randomized  intervention  trials  [33,34].  The
ir  Force/Texas  Coronary  Atherosclerosis  Prevention  Study
AFCAPS/TexCAPS)  illustrated  the  beneﬁts  of  intervening  to
orrect  the  lipid  proﬁle  in  a  patient  population  with  low
DL  cholesterol  at  baseline  [35], and  patients  with  the  low-
st  HDL  cholesterol  appeared  to  derive  greatest  beneﬁts
rom  intervention  with  a  statin,  consistent  with  their  higher
[[
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overall  cardiovascular  risk  [36]. In  our  study,  the  observed
relationship  between  HDL  cholesterol  and  VH-derived  TCFA
raises  the  possibility  that  HDL  cholesterol  might  be  an
attractive  target  for  modifying  the  high-risk  patient  among
those  with  SAP.  Also,  it  is  possible  that  the  recovery  of  low
HDL  cholesterol  level  might  be  a  useful  indicator  to  assess
the  efﬁcacy  of  such  treatments  for  secondary  prevention  of
cardiovascular  events  in  SAP  patients.
Study  limitations
This  study  has  several  limitations.  First,  the  present  study  is
a  retrospective  single-center  study,  so,  is  subject  to  limita-
tions  inherent  in  this  type  of  clinical  investigation.  Second,
IVUS  and  VH-IVUS  imaging  were  performed  at  the  discre-
tion  of  the  individual  operators,  so  these  situations  might
lead  to  potential  selection  bias.  Third,  heavily  calciﬁed
plaques  may  induce  an  artifact  regarding  the  codiﬁcation
of  plaques  by  VH-IVUS  resulting  in  an  increment  of  NC  con-
tent.  Fourth,  VH-IVUS  is  a  weak  tool  to  detect  VP.  The
reason  for  that  comes  from  the  insufﬁcient  spatial  resolution
of  commercially  available  VH-IVUS,  although  the  PROSPECT
trial  provided  evidence  that  VH-derived  TCFA  are  related  to
future  cardiovascular  events  [25]. A  larger  and  more  ade-
quately  powered  prospective  investigation  may  be  needed
to  verify  the  results  of  this  study.
Conclusions
VH-derived  TCFA  is  not  a  frequent  plaque  type  lesion  sub-
mitted  to  intervention  in  SAP  patients,  and  MetS  is  not  an
independent  predictor  of  VH-derived  TCFA  as  culprit  lesion
in  SAP  patients.
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